Vista Pharmaceuticals sets Aug 14, 2026 board meet

Key development: board meeting for June 2026 quarter

Vista Pharmaceuticals Ltd informed BSE that its Board of Directors is scheduled to meet on 14 August 2026. The agenda includes the approval of unaudited financial results for the quarter ended 30.06.2026. Such board meeting intimations matter because they signal when the next set of numbers will be placed before the market. For small-cap counters, results dates can also influence near-term liquidity and spreads.

Stock snapshot around the disclosure

Trading indicators included a last-traded move of -0.34 (-4.93%) as on 14 Aug, 2026 | 09:29. The available bid/ask at that time was ₹6.58 / ₹6.90, indicating a relatively wide spread. Another snapshot showed -0.39 (-5.66%) as on 07 Aug, 26 | 15:50. A separate BSE print showed ₹6.50, down ₹0.13 (-1.96%) on 31 Jul | 04:01 PM. The text also stated: “The current share price of Vista Pharmaceutical is ₹6.63.”

What the company told BSE for Aug 14

The disclosure described the meeting as a board meeting intimation for approval of unaudited financial results for the quarter ended 30 June 2026. Beyond the limited text provided, the central point is the scheduled decision-making date for the quarterly numbers. Investors typically watch for the filing of financial statements and any accompanying limited review observations when unaudited results are released.

Earlier results: March 2026 quarter performance

For the quarter ended March 31, 2026, the company reported a standalone net loss of ₹5.86 crore, with zero revenue from operations. The same report compared it with a net loss of ₹1.50 crore in the quarter ended March 2025. It also stated there were no sales in the March 2026 quarter versus ₹3.23 crore in the March 2025 quarter. The quarterly table provided alongside the update also showed net sales moving from ₹3.23 crore (Mar 2025) to ₹0.00 crore (Mar 2026).

FY26 vs FY25: loss widened, revenue declined

For the financial year ended March 31, 2026 (FY26), Vista Pharmaceuticals reported a net loss of ₹12.06 crore, compared with a net loss of ₹4.65 crore in FY25. Revenue from operations was reported at ₹5.40 crore for FY26 versus ₹10.07 crore in FY25, with the report noting a 46.38% decline. Another statement in the provided text expressed the same revenue numbers in lakhs: ₹539.95 lakh in FY26 versus ₹1,007.46 lakh in FY25, which corresponds to ₹5.40 crore and ₹10.07 crore respectively after unit conversion.

Board meeting on May 29, 2026: audited results approved

The company said the Board of Directors approved the audited standalone financial results for the quarter and year ended March 31, 2026 at a meeting held on May 29, 2026. The meeting was scheduled to be held at the company’s registered office in Hyderabad, according to the text. It also stated that the statutory auditors, M/s. A.M Reddy & D.R. Reddy, issued an unmodified opinion on the financial results.

Quarterly financials table: recent trend (₹ crore)

The following quarterly figures (all in ₹ crore, EPS in ₹) were included in the provided data.

Timeline of key corporate and results-related updates

The provided material also included multiple board meeting references and corporate calendar items.

Corporate actions and management changes disclosed

The corporate updates section said the board recommended reappointment of two directors retiring by rotation: Mr. Umakanth Katta and Mr. Divakar Reddy Yerrabommanahalli. It also recorded executive reappointments for three-year terms starting October 19, 2025, subject to shareholder approval: Mr. Murali Meraga as Managing Director, and Mr. Pavan Sathvik Gilaka and Mr. Dhananjaya Alli as Whole-time Directors. Separately, an earlier quarterly update included a table (shown in lakhs) that listed revenue from operations of ₹151.88 lakh (₹1.52 crore) and net loss of ₹129.04 lakh (₹1.29 crore) for the quarter ended June 30, 2025, alongside the prior-year quarter.

Market impact: what investors typically track next

Based on the disclosures provided, the next immediate milestone is the Aug 14, 2026 board meeting for the June 2026 quarter unaudited results. Market participants generally watch for revenue trends, cost levels, and whether any sales resume after the zero revenue quarter reported for March 2026. The recent price snapshots and the bid-ask spread highlighted in the data can also be relevant for execution risk, especially when liquidity is thin.

Conclusion

Vista Pharmaceuticals’ Aug 14, 2026 board meeting intimation sets a clear date for the next quarterly update for the period ended June 30, 2026. The most recent audited period referenced in the provided material showed a widened annual loss in FY26 and a March 2026 quarter with zero revenue. The next confirmed step is the board’s consideration of the June 2026 unaudited financial results on the scheduled date, followed by the company’s filing with the exchange.